Page last updated: 2024-12-09

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2762693
MeSH IDM0191693

Synonyms (10)

Synonym
2h-tetrazolium, 5-(3-(carboxymethoxy)phenyl)-3-(4,5-dimethyl-2-thiazolyl)-2-(4-sulfophenyl)-, hydroxide, inner salt
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium
3-mts
138169-43-4
FT-0629025
DTXSID20160514
4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate
5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-2-thiazolyl)-2-(4-sulfophenyl)-2h-tetrazolium inner salt
5-[3-(carboxymethoxy)phenyl]-2-(4,5-dimethyl-1,3-thiazol-2-yl)-3-(4-sulfonatophenyl)-3h-1,2,3,4-tetrazol-2-ylium
F88556

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A modified 'amyloid cascade' hypothesis for Alzheimer's disease states that prefibrillar oligomers, also called amyloid-beta-derived diffusible ligands or globular oligomers, are the responsible toxic agent."( Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity.
Anderluh, G; Ceru, S; Gutierrez-Aguirre, I; Kopitar-Jerala, N; Macek, P; Rabzelj, S; Turk, V; Zerovnik, E, 2005
)
0.33
" In vitro, the toxic concentration 50% (TC50) of TNB, which induced cell death, was 16 microM following a 24-h exposure."( Effects of 1,3,5-Trinitrobenzene on cytotoxicity and metabolic activity of type I astrocytes of rats.
Quails, CW; Reddy, G; Ritchey, JW; Saliki, JT; Stair, EL,
)
0.13
" Silver nanoparticles were the most toxic while molybdenum trioxide (MoO(3)) nanoparticles were the least toxic."( In vitro cytotoxicity of nanoparticles in mammalian germline stem cells.
Braydich-Stolle, L; Hofmann, MC; Hussain, S; Schlager, JJ, 2005
)
0.33
" Nine out of 16 compounds were found toxic after direct exposure at 100muM while only three still induced toxicity on SH-SY5Y cells after BBB transport."( New strategy for alerting central nervous system toxicity: Integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment.
Cecchelli, R; Culot, M; Diallo, H; Hallier-Vanuxeem, D; Landry, C; Prieto, P; Tähti, H, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Polyol showed an amphiphilic character and could be prepared as a nanoparticle for the sustained delivery of raloxifene hydrochloride, a drug with poor bioavailability in aqueous solution."( Design, characterization and in vitro evaluation of novel amphiphilic block sunflower oil-based polyol nanocarrier as a potential delivery system: Raloxifene-hydrochloride as a model.
Babanejad, N; Farhadian, A; Nabid, MR; Omrani, I, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" In this pilot study, we investigated the dose-response to 1α,25-dihdroxyvitamin D(3) (1,α 25(OH)(2) D(3)) and 25-hydroxyvitamin D(3) (25(OH)D(3)) by human OS cell lines, SaOS-2, and 143B."( Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines.
Anderson, HC; Garimella, R; Keighley, J; Pinson, D; Tancabelic, J; Tawfik, O; Templeton, K; Thompson, L; Wang, S, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (16.47)18.2507
2000's30 (35.29)29.6817
2010's40 (47.06)24.3611
2020's1 (1.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.56 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other89 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]